Additionally, Shi et al. (86) developed genetically engineered exosomes with anti-CD3 and anti-HER2 antibodies to produce SMART- Exos, which showed highly effective and selective induction of tumor-specific immunity expressing HER2 both in vitro and in vivo, thus creating an innovative class of immunotherapy against HER2-positive breast cancer (86). This evidence concerns the gene ERBB2 and breast carcinoma.